Rifabutin prophylaxis against Mycobacterium avium complex infections in HIV-infected patients: Impact on the incidence of campylobacteriosis

AIDS Patient Care and STDs

Volumn 13, Issue 8, 1999, Pages 467-472

  Pulik, Marc ^a,b   Genet, Philippe ^a   Leturdu, Françoise ^a   Lionnet, François ^a   Louvel, Delphine ^a   Touahri, Tahar ^a  

^a CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^b Department of Hematology ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN; GENTAMICIN; NALIDIXIC ACID; PEFLOXACIN; RIFABUTIN;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; CAMPYLOBACTER JEJUNI; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTICS, ANTITUBERCULAR; CAMPYLOBACTER INFECTIONS; CD4 LYMPHOCYTE COUNT; FEMALE; FRANCE; HUMANS; INCIDENCE; MALE; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RETROSPECTIVE STUDIES; RIFABUTIN; SEXUALITY; TIME FACTORS;

EID: 0032869070     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729199318192     Document Type: Article

References (18)

1. Blaser MJ, Wells JO, Feldman RA, Pollard RA, Allen JR, and the Collaborative Diarrheal Disease Study Group. Campylobacter enteritis in the United States: A multicenter study. Ann Intern Med 1983;98:360-365.
2. Sorvillo FJ, Lieb IE, Waterman SH. Incidence of campylobacteriosis among patients with AIDS in Los Angeles county. J Acquir Immune Defic Syndr 1991;4:598-602.
3. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;329:828-833.
4. Masur H, and the Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium Avium Complex. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 1993;329:898-904.
5. Van der Auwera P, Scomeaux B. In vitro susceptibility of Campylobacter jejuni to 27 antimicrobial agents and various combinations of β-lactams with clavulanic acid or sulbactam. Antimicrob Agents Chemother 1985;28:37-40.
6. Penner JL. Campylobacter, Helicobacter, and related spiralbacteria. In: Balows A, Hausler WJ, Herrman KL, Isenverg HD, Shadomy HL, eds. Manual of Clinical Microbiology, 5th ed. Washington DC: American Society for Microbiology, 1991, pp. 402-409.
7. Angulo FJ, Swerdlow DL. Bacterial enteric infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21(Suppl. 1):S84-93.
8. Allos BM, Blaser MJ. Campylobacter jejuni and the expanding spectrum of related infections. Clin Infect Dis 1995;20:1092-1099.
9. Nelson MR, Shanson DC, Hawkins DA, Gazzard BG. Salmonella, Campylobacter and Shigella in HIV-seropositive patients. AIDS 1992;6:1495-1498.
10. Molina JM, Casin I, Hausfater P, et al. Campylobacter infections in HIV-infected patients: Clinical and bacteriological features. AIDS 1995;9:881-885.
11. Dworkin B, Wormsor GP, Abdoo RA, Cabello F, Aguero ME, Sivak SL. Persistence of multiply antibiotic-resistant Campylobacter jejuni in a patient with the acquired immune deficiency syndrome. Am J Med 1986;80:965-970.
12. Perlman DM, Ampbel NM, Schifman RB, Cohn DL, Patton CM, Aguirre ML, et al. Persistent Campylobacter jejuni infections in patients infected with human immunodeficiency virus (HIV). Ann Intern Med 1988;108:540-546.
13. Bernard E, Roger PM, Carles D, Bonaldi V, Fournier JP, Dellamonica P. Diarrhea and Campylobacter infections in patients infected with the human immunodeficiency virus. J Infect Dis 1989;159:143-144.
14. Tee W, Mijch A, Wright E, Yung A. Emergence of multidrug resistance in Campylobacter jejuni isolates from three patients infected with human immunodeficiency virus. Clin Infect Dis 1995;21:634-638.
15. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-1090.
16. Gallicano K, Sahai J, Swick L, Seguin I, Pakuts A, Cameron DW. Effect of rifabutin in the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. Clin Infect Dis 1995;21:1008-1011.
17. Sahai J, Narang PK, Hawley-Foss N, Li RC, Kamal M, Cameron DW. A Phase I evaluation of concomitant rifabutin and didanosine in symptomatic HIV-infected patients. J AIDS 1995;9:274-279.
18. Patella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.